CliffBio
small molecule

XIMINO

MINOCYCLINE HYDROCHLORIDE

Loss of exclusivityApril 2027latest FDA-listed patent expiry
CompanyJOURNEY MEDICAL CORP

Drug detail

Brand nameXIMINO
Active ingredientMINOCYCLINE HYDROCHLORIDE
StrengthEQ 135MG BASE
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2012
Marketing statusDISCN

Listed patents

PatentExpiresType
7541347April 2027use U-917
7544373April 2027product
7919483March 2027use U-124

More from JOURNEY MEDICAL CORP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XIMINO patent cliff — loss of exclusivity April 2027 | CliffBio